Abpro Holdings, Inc. (ABPO)
OTCMKTS · Delayed Price · Currency is USD
0.2185
0.00 (0.00%)
At close: Aug 19, 2026
Abpro Holdings Employees
As of December 31, 2025, Abpro Holdings had 3 total employees, including 1 full-time and 2 part-time employees. The number of employees decreased by 12 or -80.00% compared to the previous year.
Employees
3
Change (1Y)
-12
Growth (1Y)
-80.00%
Revenue / Employee
n/a
Profits / Employee
$1,005,500
Market Cap
1.29M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 3 | -12 | -80.00% | 1 | 2 |
| Dec 31, 2024 | 15 | - | - | 6 | 9 |
| Sep 30, 2024 | 16 | - | - | 15 | 1 |
| Jun 30, 2024 | 16 | - | - | 15 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Emmaus Life Sciences | 33 |
| Evofem Biosciences | 29 |
| CERo Therapeutics Holdings | 8 |
| AXIM Biotechnologies | 7 |
| ZyVersa Therapeutics | 6 |
| Avenue Therapeutics | 1 |
| Bio-Path Holdings | 1 |
Abpro Holdings News
- 5 days ago - Abpro Holdings Quarterly report: Q2 2026 - Filings
- 3 months ago - Abpro Holdings Quarterly report: Q1 2026 - Filings
- 4 months ago - Abpro Holdings Annual report: Q4 2025 - Filings
- 7 months ago - Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 8 months ago - Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - GlobeNewsWire
- 8 months ago - Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - GlobeNewsWire
- 9 months ago - Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - GlobeNewsWire
- 9 months ago - Abpro Holdings Registration statement: Registration Filing - Filings